small molecule

ARYMO ER

MORPHINE SULFATE

Loss of exclusivityJuly 2033latest FDA-listed patent expiry
CompanyZYLA LIFE SCIENCES US INC

Drug detail

Brand nameARYMO ER
Active ingredientMORPHINE SULFATE
Strength15MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
9549899July 2033product
9044402July 2033product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ARYMO ER patent cliff — loss of exclusivity July 2033 | CliffBio